ASTERDM Aster DM Healthcare Q4 FY25 results (Jan–Mar 2025) and concall
Aster DM Healthcare delivered a strong full-year performance in FY25, characterized by significant margin expansion and strategic restructuring, including the GCC demerger and the announced QCIL merger. While Q4 revenue was temporarily dampened by seasonal factors (Ramadan) and management transitions in the Kerala cluster, the company maintained high profitability. Management is pivoting toward a high-growth India-focused strategy with aggressive bed expansion and a clear roadmap to 23-24% EBITDA margins.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1,086 | 1,050 | 1,000 |
| EBITDA | 217 | 186 | 182 |
| Net profit | 106 | 64 | 86 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
